Application of cordyceps sinensis superfine powder in preparation of medicine for treating type 2 diabetes and complications thereof caused by high fat diet

Abstract

The invention discloses application of cordyceps sinensis superfine powder in preparation of a medicine for treating type 2 diabetes and complications thereof caused by high fat diet. The particle size of the cordyceps sinensis superfine powder is 105.53 [mu] m to 6.55 [mu] m, and the particle size of the cordyceps sinensis superfine powder is 63.98 [mu] m to 4.44 [mu] m. The cordyceps sinensis superfine powder shows good effects of reducing hyperglycemia and hyperlipidemia, improving insulin resistance, recovering the body weight of a diabetic patient and protecting the liver and the kidney, and the invention provides preparation and application of the cordyceps sinensis superfine powder for treating type 2 diabetes caused by high fat diet and related complications thereof. A new raw material and a new direction are provided for developing related biological medicines and health-care products for effectively treating type 2 diabetes and complications thereof.

Description

Technical field:

[0001] The invention belongs to the field of biomedicine, and specifically relates to the application of cordyceps superfine powder in preparing medicine for treating type 2 diabetes and its complications caused by high-fat diet. Background technology:

[0002] According to the 10th edition of the Global Diabetes Atlas released by the International Diabetes Federation (IDF), in 2021, about 540 million people in the world suffer from diabetes, and the number of adults aged 20 to 79 with diabetes is as high as 537 million, of which type 2 diabetes (T2MD) accounts for more than 90%; it is expected that the number of people with diabetes will rise to 643 million in 2030 and 783 million by 2045. After tumors and cardiovascular diseases, diabetes has become the third largest non-communicable chronic disease threatening human health worldwide. China is the country with the largest number of diabetes patients in the world. In 2021, the number of patients reached 140.9 million, accounting for 26.2% of the total number of patients in the world, and it is expected to reach 174.4 million in 2045. Diabetes increases the risk and mortality of cardiovascular disease, kidney disease and cancer in patients, significantly increases the economic burden on patients, and the patient population is getting younger and younger, which has a serious impact on the health of the public. At present, hypoglycemic drugs used to treat type 2 diabetes have side effects such as hypoglycemia, gastrointestinal spasm, and weight loss. Therefore, how to effectively treat type 2 diabetes and improve related complications with fewer side effects is a focus that is receiving increasing attention.

[0003] Cordyceps sinensis is a rare and precious medicinal fungus resource distributed in East Asia, North America and Southeast Asia. China has the richest resources of Cordyceps sinensis, which has a history of thousands of years of medicinal use. Cordyceps sinensis is rich in nutritional active ingredients such as cordycepic acid, adenosine, phenolic acid, nucleosides, polysaccharides, peptides, sterols and fatty acids, and has medicinal effects such as protecting the heart, immune regulation, anti-fatigue, protecting the kidneys, anti-depression, and protecting the lungs. At present, research on the medicinal effects of Cordyceps sinensis mainly focuses on crude extracts or a specific type of active ingredients. There are no reports on the use of Cordyceps sinensis fruiting body ultrafine powder and related products in the treatment of diabetes and related complications. Summary of the invention:

[0004] The purpose of the present invention is to provide the use of superfine cordyceps powder in the preparation of a drug for treating type 2 diabetes and its complications caused by a high-fat diet. The superfine cordyceps powder can effectively control the increase of blood sugar and blood lipids, insulin resistance and weight loss caused by type 2 diabetes, and show a significant effect of protecting the liver and kidneys.

[0005] The first object of the present invention is to provide the use of Cordyceps sinensis superfine powder in preparing a medicine for treating type 2 diabetes and its complications caused by a high-fat diet.

[0006] Preferably, the preparation method of the cordyceps superfine powder is to dry the cordyceps fruiting bodies and insect bodies in an oven at 50°C to 60°C, ultra-low temperature crush them in a grinder at -20°C to -15°C for 10 to 20 minutes, and obtain the cordyceps superfine powder after drying. The cordyceps superfine powder has a length of 105.53 μm to 6.55 μm and a width of 63.98 μm to 4.44 μm.

[0007] According to some embodiments of the present invention, the high-fat diet causes type 2 diabetes and its complications include weight loss, abnormally high fasting blood sugar, glucose intolerance, insulin resistance, abnormally high blood lipid indicators, non-alcoholic fatty liver or kidney damage.

[0008] According to an embodiment of the present invention, the application is the application of Cordyceps sinensis ultrafine powder in the preparation of restoring weight loss caused by type 2 diabetes, improving glucose intolerance and insulin resistance caused by type 2 diabetes, reducing serum insulin levels and insulin resistance coefficients in type 2 diabetes, reducing total cholesterol, triglycerides and low-density lipoprotein cholesterol levels and alanine aminotransferase activity, aspartate aminotransferase and alkaline phosphatase activity in serum of type 2 diabetes, improving liver fat accumulation and glassy cavitation lesions, and alleviating the degree of kidney tissue damage.

[0009] According to the embodiment of the present invention, the application is that the Cordyceps sinensis ultrafine powder is significant in the preparation of improving weight loss in patients with type 2 diabetes, controlling elevated blood sugar and blood lipids, improving insulin resistance, improving non-alcoholic fatty liver disease and improving renal cavitation degeneration, and there is no significant difference in therapeutic effect compared with the drug positive control (metformin). This is the biggest innovation of the present invention and provides a scientific basis for the development and application of blood sugar lowering, blood lipid lowering, liver protection and kidney protection related products in the future in the fields of health products and medicine.

[0010] Preferably, the drug also includes pharmaceutically usable excipients and is prepared into various usable dosage forms.

[0011] According to some embodiments of the present invention, the above-mentioned Cordyceps sinensis ultrafine powder has the effects of controlling elevated blood sugar and blood lipids and improving glucose and lipid metabolism, weight loss caused by type 2 diabetes, non-alcoholic fatty liver and renal cavitation lesions, etc., has potential huge economic value and good social effects, and can promote the rapid development of Cordyceps-related industries.

[0012] The cordyceps superfine powder for treating type 2 diabetes and its related complications of the present invention can improve the abnormal glucose and lipid metabolism of type 2 diabetic mice induced by high-fat diet and streptozotocin, treat related complications caused by type 2 diabetes such as weight loss, non-alcoholic fatty liver and kidney damage, improve insulin resistance of type 2 diabetic mice, and reduce their blood sugar.

[0013] Therefore, the superfine powder of Cordyceps sinensis exhibits good effects of lowering blood sugar, lowering blood lipids, protecting the liver and protecting the kidneys. The present invention provides a preparation method and application of superfine powder of Cordyceps sinensis for treating type 2 diabetes and its complications caused by a high-fat diet, providing a new raw material and a new direction for the development of related biopharmaceuticals and health products that effectively treat type 2 diabetes and its complications. Description of the drawings:

[0014] Figure 1 The microstructure of the Cordyceps superfine powder of the present invention (400×).

[0015] Figure 2 The effects of different concentrations of Cordyceps superfine powder of the present invention on body weight (A), fasting blood sugar (B), fasting insulin (C), insulin resistance coefficient (homeostatic model assessment method HOMA-IR) (D), oral glucose tolerance test OGTT (E), area under the curve AUC of OGTT (F), insulin tolerance test ITT (G) and AUC of ITT (H) of type 2 diabetic mice. Control group: normal mouse group; model group: type 2 diabetes model group; metformin: positive control group; low concentration of superfine powder: 0.5g / kg / d Cordyceps superfine powder group; high concentration of superfine powder: 2g / kg / d Cordyceps superfine powder group. Note: Compared with the control group mice, ***P<0.001; compared with the model group, ###P<0.001. P<0.01 means there is a significant statistical difference, and P<0.001 means there is an extremely significant statistical difference.

[0016] Figure 3 The effect of the Guangdong Cordyceps hypoglycemic formula of the present invention on total cholesterol (A), triglycerides (B) and low-density lipoprotein cholesterol (C) in the serum of type 2 diabetic mice. Control group: normal mouse group; Model group: type 2 diabetes model group; Metformin: positive control group; Ultrafine powder low concentration: 0.5g / kg / d Cordyceps superfine powder group; Ultrafine powder high concentration: 2g / kg / d Cordyceps superfine powder group. Note: Compared with the control group mice, ***P<0.001; compared with the model group, #P<0.05, ##P<0.01, ###P<0.001. P<0.05 means there is a statistical difference, P<0.01 means there is a significant statistical difference, and P<0.001 means there is an extremely significant statistical difference.

[0017] Figure 4The effects of the Guangdong Cordyceps hypoglycemic formula of the present invention on liver weight (A) and serum alanine aminotransferase activity (B), aspartate aminotransferase activity (C), alkaline phosphatase activity (D), glutathione activity (E), superoxide dismutase activity (F), and peroxidase activity (G) of type 2 diabetic mice, as well as liver H&E staining (H) and Oil Red O staining (I) pathological section observation (200×). Control group: normal mouse group; model group: type 2 diabetes model group; metformin: positive control group; ultrafine powder low concentration: 0.5g / kg / d Cordyceps ultrafine powder group; ultrafine powder high concentration: 2g / kg / d Cordyceps ultrafine powder group. Note: Compared with the control group mice, ***P<0.001; compared with the model group, #P<0.05, ###P<0.001. P<0.05 means there is a statistical difference, and P<0.001 means there is an extremely significant statistical difference.

[0018] Figure 5 The effect of the Guangdong Cordyceps hypoglycemic formula of the present invention on the kidney weight of type 2 diabetic mice (A) and the kidney H&E staining (B) pathological section observation (200×). Control group: normal mouse group; model group: type 2 diabetes model group; metformin: positive control group; superfine powder low concentration: 0.5g / kg / d Cordyceps superfine powder group; superfine powder high concentration: 2g / kg / d Cordyceps superfine powder group. Specific implementation method:

[0019] The present invention will be described in detail below in conjunction with the examples. The experimental methods used in the examples are conventional experimental methods unless otherwise specified. The materials, reagents, etc. used in the examples can be obtained from commercial sources unless otherwise specified.

[0020] Cordyceps sinensis was purchased from the Cordyceps Trading Market in Senyi District, Nagqu City, Tibet; SPF-grade C57BL / 6J male mice were purchased from Zhejiang Weitonglihua Experimental Animal Technology Co., Ltd., license number: SCXK (Zhejiang) 2019-0001.

[0021] Example 1

[0022] 1. Experimental Methods

[0023] The superfine Cordyceps sinensis powder of the present embodiment is obtained by drying the fruiting bodies and insect bodies of Cordyceps sinensis in an oven at 50°C to 60°C, ultra-low temperature pulverizing them in a pulverizer at -20°C to -15°C for 10 to 20 minutes, and drying them to obtain the superfine Cordyceps sinensis powder.

[0024] The detailed steps of mouse grouping, modeling and drug administration are as follows:

[0025] 1. Mouse grouping: The experimental animals were 30 6-week-old SPF-grade C57BL / 6J male mice, weighing 18-20 g, and were raised in the Experimental Animal Center of the Institute of Microbiology, Guangdong Academy of Sciences, at a temperature of 21±2°C, a humidity of 55±10%, 12h light and dark alternation, and free drinking water. After one week of adaptive culture, they were randomly divided into a control group, a model group, a metformin group (positive control group), a low-concentration ultrafine powder group, and a high-concentration ultrafine powder group, with 6 mice in each group.

[0026] 2. Modeling: The mice in the control group were fed with ordinary feed, and the mice in the model group, metformin group, ultrafine powder low concentration group and ultrafine powder high concentration group were fed with 60% high-fat feed. After 7 weeks, all mice were fasted but not watered for 12 hours. Except for the control group, the mice in the other groups were given a single intraperitoneal injection of 100 mg / kg of 1% streptozotocin solution (dissolved in 0.1 mol / L, pH=4.5, 4°C sodium citrate buffer solution) to induce type 2 diabetes model, while the mice in the control group were given an intraperitoneal injection of an equal volume of sodium citrate buffer solution. One week later, the fasting blood glucose levels of the mice in each group were measured, and the fasting blood glucose value ≥11.1mmol / L was used as the modeling standard.

[0027] 3. Drug administration: After successful modeling, the ultrafine powder low concentration group and high concentration group were gavaged with 0.5g / kg / d and 2.0g / kg / d of Cordyceps sinensis ultrafine powder, respectively, the positive control group was gavaged with 0.2g / kg / d of metformin, and the control group and model group mice were gavaged with the same volume of normal saline. During the entire experiment, except for the control group, which was fed with ordinary feed, the other groups were fed with high-fat feed. The fasting blood glucose level and body weight of the mice were measured once a week, and the mice were free to eat and drink water during the experiment.

[0028] 2. Experimental Results

[0029] 1. Observation of the morphology of Cordyceps sinensis ultrafine powder:

[0030] After the Cordyceps sinensis was ultra-low temperature pulverized in a -20℃~-15℃ grinder for 10~20min, the morphological structure of the ultrafine powder was observed using an electron optical microscope (Nikon DS-Ri2). The length of the Cordyceps sinensis ultrafine powder was 105.53μm~6.55μm, and the width was 63.98μm~4.44μm ( Figure 1 ).

[0031] 2. Effects of Cordyceps sinensis ultrafine powder on body weight and glucose metabolism in mice with type 2 diabetes induced by high-fat diet and streptozotocin:

[0032] On the last day of the fourth week of administration, an oral glucose tolerance test (OGTT) was performed on mice: after fasting for 12 hours but not water deprivation, mice were gavaged with 2 g / kg glucose solution, and tail vein blood was collected at 0, 30, 60, 90, and 120 minutes to measure blood glucose levels, and the area under the OGTT curve AUC was calculated. After 5 weeks of administration, an insulin tolerance test (ITT) was performed on mice: after fasting for 4 hours but not water deprivation, mice were intraperitoneally injected with 1 U / kg insulin, and tail vein blood was collected at 0, 30, 60, 90, and 120 minutes to measure blood glucose levels, and the area under the ITT curve AUC was calculated. Three days after the end of the ITT experiment, mice were fasted for 12 hours overnight, weighed before sampling, blood glucose was measured, anesthetized with carbon dioxide, and blood was collected by cardiac puncture. After equilibration at room temperature for 2 hours, the blood was centrifuged at 3000 rpm for 15 minutes at 4°C, and the upper serum was collected. According to the instructions of the kit, the enzyme-linked immunosorbent assay (ELISA) was used to detect the serum insulin level of mice and evaluate the HOMA-IR model of mice.

[0033] The results are as follows Figure 2 As shown: Compared with the control group mice, the body weight of the model group mice was significantly reduced (P<0.001, Figure 2 A), while fasting blood glucose, serum insulin level and HOMA-IR model values ​​increased significantly (P<0.001, Figure 2 BD), glucose tolerance and insulin resistance were abnormal (P<0.001, Figure 2 E and G), and the areas under the OGTT and ITT curves increased significantly (P<0.001, Figure 2 F and H). Compared with the model group, the body weight of mice in the low-concentration and high-concentration Cordyceps superfine powder groups was significantly increased (P<0.001), and the fasting blood glucose value, serum insulin level, and HOMA-IR model value were significantly reduced (P<0.001). Glucose tolerance and insulin tolerance were significantly improved (P<0.001), and the area under the OGTT and ITT curves was significantly reduced (P<0.001). Compared with the positive control metformin group, there was no significant difference in the body weight recovery level and fasting blood glucose value of mice in the low-concentration Cordyceps superfine powder group, and there was no significant difference in the body weight recovery level, fasting blood glucose value, insulin level, and insulin resistance index of mice in the high-concentration Cordyceps superfine powder group. The above results show that Cordyceps superfine powder has a significant effect on improving glucose metabolism in mice with type 2 diabetes induced by high-fat diet and streptozotocin, and there is no significant difference in restoring body weight and reducing fasting blood glucose values ​​compared with the positive control.

[0034] 3. Effects of Cordyceps sinensis ultrafine powder on hyperlipidemia in mice induced by high-fat diet and streptozotocin:

[0035] On the 38th day after administration of different treatments, all mice were fasted but not watered for 12 hours, and then weighed. Blood was collected by cardiac puncture under carbon dioxide anesthesia, placed in a centrifuge tube at room temperature for 2 hours, and centrifuged at 4°C and 3000 rpm for 15 minutes to collect the upper serum. The total cholesterol, triglyceride and low-density lipoprotein cholesterol levels of the mice in the five groups were measured using a kit.

[0036] The results are as follows Figure 3 As shown: Compared with the control group, the serum total cholesterol, triglyceride and low-density lipoprotein cholesterol levels of the model group mice were significantly increased (P<0.001, Figure 3 AC), indicating that high-fat diet and streptozotocin-induced type 2 diabetes mice showed significant increase in blood lipids. After 38 days of administration, compared with the model group mice, the serum total cholesterol and low-density lipoprotein cholesterol levels of the mice in the low-concentration and high-concentration groups of Cordyceps sinensis superfine powder were significantly reduced (P<0.05, Figure 3 B and C in Figure 1). Compared with the positive control metformin group, there were no significant differences in the three blood lipid indexes in the serum of mice in the two cordyceps superfine powder treatment groups. The above results show that cordyceps superfine powder can improve the dyslipidemia of mice with type 2 diabetes induced by high-fat diet and streptozotocin, and the effect is not significantly different from the positive control.

[0037] 4. Effects of Cordyceps sinensis ultrafine powder on liver-related indicators and microstructural observation of type 2 diabetic mice:

[0038] On the 38th day after administration of different treatments, all mice were fasted but not watered for 12 hours, anesthetized with carbon dioxide, and blood was collected by cardiac puncture. The blood was placed in a centrifuge tube at room temperature for 2 hours, centrifuged at 4°C and 3000rpm for 15 minutes, and the upper serum was collected. The levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, glutathione, superoxide dismutase, and catalase in the five groups of mice were measured using a kit. At the same time, the largest lobe of the liver tissue was fixed in 4% paraformaldehyde and then paraffin sectioned; dewaxed in fresh xylene I and xylene II, and then dehydrated in anhydrous ethanol, 90%, 80%, and 70% ethanol in turn, and the residual ethanol was washed off with distilled water, and stained with hematoxylin for 5 minutes; the excess stain was washed off with distilled water, and 1% hydrochloric acid ethanol was added for differentiation, and eosin staining solution was added for 2 minutes; dehydrated in gradient ethanol in turn, transparent in xylene, and finally sealed with neutral resin. Take the frozen liver sections, gently immerse them in Oil Red O working solution, cover and avoid light for 10 minutes, then immerse them in two cylinders of 60% isopropanol for differentiation, rinse them in two cylinders of pure water, add hematoxylin for re-staining for 5 minutes after immersion, rinse them in three cylinders of pure water, differentiate them with hydrochloric acid ethanol, return them to blue with blue solution, rinse them with distilled water, and finally seal them with glycerol gelatin. The pathological sections after the above staining were observed using a Leica DM6M electron microscope.

[0039] The results are as follows Figure 4 As shown in Figure 2, compared with the control group, the liver index and serum aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase activities of the model group mice were significantly increased (P<0.001, Figure 4 AD), while the activities of serum glutathione, superoxide dismutase and catalase were significantly decreased (P<0.001, Figure 4 EG), the liver cells of the model group mice were disorderly arranged, showing a large area of ​​deep red, small and dense lipid droplets filled the liver cells, and there were a large number of vacuolar degeneration ( Figure 4 H and I), indicating that a large number of lipid droplets accumulated in the liver cells of mice with type 2 diabetes induced by high-fat diet and streptozotocin, showing obvious fatty degeneration and severe oxidative damage. Compared with the model group mice, the liver index and serum aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase activities of mice in the low-concentration and high-concentration groups of Cordyceps superfine powder were significantly reduced (P<0.001), while the activities of glutathione, superoxide dismutase and catalase in serum were significantly increased (P<0.05). The liver cells of mice in the two Cordyceps superfine powder treatment groups were arranged more regularly and tightly, showing light red and a small amount of vacuolar degeneration, and lipid droplet accumulation and fatty degeneration were significantly improved. Compared with the positive control metformin group, only the low-concentration Cordyceps sinensis powder group had significantly reduced alanine aminotransferase activity (P<0.05), and the other six groups of mice treated with two Cordyceps sinensis powders had no significant difference from the positive control group. The accumulation of lipid droplets and fatty degeneration in the liver of mice treated with high-concentration Cordyceps sinensis powder were closer to those in the positive control group. The above results indicate that Cordyceps sinensis powder can improve liver fatty degeneration and oxidative damage in mice with type 2 diabetes induced by high-fat diet and streptozotocin, treat non-alcoholic fatty liver disease and protect the liver.

[0040] 5. Effects of Cordyceps sinensis ultrafine powder on kidney-related indicators and microstructural observation of type 2 diabetic mice:

[0041] On the 38th day after administration of different treatments, all mice were fasted but not watered for 12 hours, anesthetized with carbon dioxide, blood was collected by cardiac puncture, kidney tissue was weighed, and then fixed in 4% paraformaldehyde, and then paraffin sectioned; dewaxed in fresh xylene I and xylene II, and then dehydrated in anhydrous ethanol, 90%, 80%, and 70% ethanol in turn, and residual ethanol was washed away with distilled water, and stained with hematoxylin for 5 minutes; the excess dye was washed away with distilled water, and 1% hydrochloric acid ethanol was added for differentiation, and eosin staining solution was added for 2 minutes; dehydrated in gradient ethanol in turn, transparent in xylene, and finally sealed with neutral resin. The pathological sections after the above staining were observed using a Leica DM6M electron microscope.

[0042] The results are as follows Figure 5As shown: Compared with the control group, the renal index of the model group mice was significantly increased (P<0.001, Figure 5 A), the kidneys of mice in the model group showed obvious renal hypertrophy, the glomerular volume was significantly enlarged, and the renal tubular epithelium and cytoplasm showed severe cavitation degeneration ( Figure 5 B). Compared with the model group, the renal index of mice in the low-concentration and high-concentration groups of Cordyceps sinensis was significantly reduced (P<0.001), and renal hypertrophy, glomerular enlargement, and vacuolar degeneration of renal tubular epithelium and cytoplasm were significantly improved. Compared with the positive control group, there was no significant difference in the renal index of mice in the two Cordyceps sinensis ultrafine powder treatment groups, and the improvement effect of vacuolar degeneration of renal tubular epithelium and cytoplasm in the high-concentration group of ultrafine powder was better than that in the positive control group. The above results show that Cordyceps sinensis ultrafine powder can improve renal vacuolar pathology and glomerular volume enlargement in mice with type 2 diabetes induced by high-fat diet and streptozotocin.

[0043] In summary, superfine Cordyceps sinensis powder can improve abnormal glucose metabolism, insulin resistance and abnormal lipid metabolism in type 2 diabetic mice induced by high-fat diet and streptozotocin, treat type 2 diabetes-related complications such as weight loss, non-alcoholic fatty liver and kidney damage, and reduce hyperglycemia and hyperlipidemia in type 2 diabetic mice.

[0044] Therefore, the superfine Cordyceps sinensis powder shows good effects of reducing hyperglycemia and hyperlipidemia, and protecting the liver and kidneys. The present invention provides a preparation method and application of superfine Cordyceps sinensis powder for treating type 2 diabetes and its related complications caused by a high-fat diet, providing a new raw material and a new direction for the development of related biopharmaceuticals and health products that are effective in treating type 2 diabetes and its complications.

[0045] The above are only some embodiments of the present invention. However, the present invention is not limited to the above embodiments, and there are many variations. All direct outputs or modified outputs of the content completed under the technical spirit suggested by the present invention should belong to the protection scope of the present invention.

Claims

1. Application of Cordyceps sinensis ultrafine powder in the preparation of drugs for treating type 2 diabetes and its complications caused by high-fat diet.

2. The use according to claim 1, characterized in that: The preparation method of the cordyceps superfine powder is as follows: drying the cordyceps fruiting bodies and insect bodies in an oven at 50-60°C, ultra-low temperature crushing in a grinder at -20--15°C for 10-20 minutes, and obtaining the cordyceps superfine powder after drying.

3. The use according to claim 1, characterized in that: The high-fat diet causes type 2 diabetes and its complications, including weight loss, abnormally high fasting blood sugar, glucose intolerance, insulin resistance, abnormally high blood lipid indexes, non-alcoholic fatty liver or kidney damage.

4. The use according to claim 1, characterized in that: The application is the application of cordyceps superfine powder in the preparation of restoring weight loss caused by type 2 diabetes, improving glucose intolerance and insulin resistance caused by type 2 diabetes, reducing serum insulin level and insulin resistance coefficient of type 2 diabetes, reducing total cholesterol, triglyceride and low-density lipoprotein cholesterol content and alanine aminotransferase activity, aspartate aminotransferase and alkaline phosphatase activity in serum of type 2 diabetes, improving liver fat accumulation and glassy cavitation lesions, and alleviating the degree of kidney tissue damage.

5. The use according to claim 1, characterized in that: The application is the application of Cordyceps sinensis ultrafine powder in the preparation of improving weight loss in patients with type 2 diabetes, controlling elevated blood sugar and blood lipids, improving insulin resistance, improving non-alcoholic fatty liver and improving renal cavitation degeneration. The effect is significant and has no significant difference with the therapeutic effect of the drug metformin. This is the biggest innovation of the present invention and provides an experimental basis for the development and application of blood sugar lowering, blood lipid lowering, liver protection and kidney protection related products in the future in the fields of health care products and medicine.

6. The use according to claim 1, characterized in that: The medicine also includes pharmaceutically usable auxiliary materials and is prepared into various usable dosage forms.

Images